Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19

Contemporary Clinical Trials(2021)10.1016/j.cct.2021.106330Source: DataRank Database

RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19 is a research paper published in Contemporary Clinical Trials (2021). On theSindex it has a DataRank of 0.733. It has been cited 14 times, with 13 citing works in its 1-hop citation network.

N/A

0.733DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access14 citations · 13 citing works in its network

Download PDF

Cite:

Linked data & code

nct doi

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT04366050

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (28 grants)OA: greenTopics (90)IDs (PubMed, PMC)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 55%Citation Network 45%

Base Score Contribution

0.406

From this paper's citation signal

Citation Network Contribution

0.327

From 9 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 13 citers.

Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19
Journal of the American Heart Association202129 citations36 referencesContributes 0.094
In-hospital use of ACE inhibitors/angiotensin receptor blockers associates with COVID-19 outcomes in African American patients
Journal of Clinical Investigation202120 citations35 referencesContributes 0.087
Hypertension and COVID-19: Current Evidence and Perspectives
High Blood Pressure & Cardiovascular Prevention2022134 citations83 referencesContributes 0.059
Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient
Inflammopharmacology20244 citations37 referencesContributes 0.043
Association of in-hospital use of ACE-I/ARB and COVID-19 outcomes in African American population
medRxiv20212 citations31 referencesContributes 0.035

Authors (12)

Wesley K. Thompson ORCID,Davey M. Smith ORCID,Atul Malhotra ORCID,Ravindra L. Mehta ORCID,Vaishal Tolia ORCID

Live enrichment

PubMed:33631357 PMC:PMC7899027

National Institute of Environmental Health Sciences

Grant: 5P42ES010337

National Center for Advancing Translational Sciences

Grant: 5UL1TR001442

U.S. Department of Defense

Grant: CA170674P2

U.S. Department of Defense

Grant: K23DK119460

U.S. Department of Defense

Grant: DK079337

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: P30DK120515

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: R01DK106419

NCATS NIH HHS

Grant: UL1 TR001442

NIEHS NIH HHS

Grant: P42 ES010337

NIDDK NIH HHS

Grant: P30 DK079337

Allergan

Grant: unidentified

unidentified

National Institutes of Health

Grant: 1R03HS013039-01

Violence &SCI: Understanding the Rehabilitation Context

National Institutes of Health

Grant: 5P30DK079337-02

UAB-UCSD O'Brien Core Center for Acute Kidney Injury Research

National Institutes of Health

Grant: 3P42ES010337-20S1

Harnessing Technological Innovation and Community-Engaged Implementation Science to Optimize COVID-19 Testing for Women and Children in Underserved Communities

National Institutes of Health

Grant: 1K23DK119460-01A1

A Novel Multimodal Approach to Characterize NAFLD Severity and Prognosis

National Institutes of Health

Grant: 1R01DK106419-01

QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD

National Institutes of Health

Grant: 2UL1TR001442-06

UC San Diego Clinical and Translational Research Institute

National Institutes of Health

Grant: 5P30DK120515-04

San Diego Digestive Diseases Research Center

Merck

Arrien Pharmaceuticals

Allergan

Novo Nordisk

Bayer Fund

Bristol-Myers Squibb

John and Mary Tu Foundation

Pfizer

National Institutes of Health

Pfizer Healthcare Ireland

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7899027

publisherhttps://api.elsevier.com/content/article/PII:S1551714421000665?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1551714421000665?httpAccept=text/plain

Europe_PMChttps://europepmc.org/articles/PMC7899027

Europe_PMChttps://europepmc.org/articles/PMC7899027?pdf=render

Fields of Study

0302 clinical medicine03 medical and health sciences

MeSH Terms

HumansRamiprilAngiotensin-Converting Enzyme InhibitorsTreatment OutcomeRespiration, ArtificialCritical CareMortalityDouble-Blind MethodAdultFemaleMaleRandomized Controlled Trials as TopicDisease Transmission, InfectiousBiomarkersCOVID-19SARS-CoV-2

Keywords

Mechanical ventilationVirtual VisitCovid-19Sars-cov2MaleCoronavirusesAngiotensin-Converting Enzyme Inhibitors11 Medical and Health Sciences (for)Medical and Health SciencesClinical Research (rcdc)Coronaviruses Therapeutics and InterventionsRamipril32 Biomedical and Clinical Sciences (for-2020)Male (mesh)General Clinical MedicineRandomized Controlled Trials as TopicArtificial (mesh)Humans (mesh)3 Good Health and Well Being (sdg)COVID-19 (mesh)RespirationTreatment Outcome (mesh)InfectiousRandomized Controlled Trials as Topic (mesh)Ramipril (mesh)Biomarkers (mesh)Infectious DiseasesTreatment Outcome6.1 PharmaceuticalsArtificialGeneral Clinical Medicine (science-metrix)FemalePatient SafetyPublic HealthAdultCritical CareAngiotensin-Converting Enzyme Inhibitors (mesh)Clinical SciencesClinical Trials and Supportive ActivitiesClinical Trials and Supportive Activities (rcdc)610Coronaviruses Therapeutics and Interventions (rcdc)SARS-CoV-2 (mesh)Emerging Infectious Diseases (rcdc)ArticleMortality (mesh)Disease TransmissionDouble-Blind MethodClinical Research42 Health sciences (for-2020)616Disease Transmission, InfectiousHumansMortalityDouble-Blind Method (mesh)3202 Clinical Sciences (for-2020)Public Health (science-metrix)6.1 Pharmaceuticals (hrcs-rac)Infectious (mesh)Biomedical and Clinical SciencesPatient Safety (rcdc)Critical Care (mesh)SARS-CoV-2Health sciencesCoronaviruses (rcdc)Respiration, ArtificialEmerging Infectious DiseasesGood Health and Well BeingInfectious Diseases (rcdc)Female (mesh)Adult (mesh)Biomarkers

Sustainable Development Goals

SDG 3: 3. Good health